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Abstract
The	 symptoms	 of	 chronic	 urticaria,	 be	 it	 chronic	 spontaneous	 urticaria	 (CSU)	 or	
chronic	 inducible	urticaria	 (CindU),	 are	mediated	primarily	by	 the	actions	of	hista‐
mine on H1	receptors	located	on	endothelial	cells	(the	weal)	and	on	sensory	nerves	
(neurogenic	flare	and	pruritus).	Thus,	second‐generation	H1	antihistamines	(sgAHs)	
are	the	primary	treatment	of	these	conditions.	However,	many	patients	are	poorly	re‐
sponsive	to	licensed	doses	of	antihistamines.	In	these	patients,	the	current	EAACI/G
A2LEN/EDF/WAO	guideline	for	urticaria	suggests	updosing	of	sgAHs	up	to	fourfold.	
However,	such	updosing	is	off‐label	and	the	responsibility	resides	with	the	prescrib‐
ing	physician.	Therefore,	the	safety	of	the	drug	when	used	above	its	licensed	dose	is	
of	paramount	importance.	An	important	aspect	of	safety	is	potential	cardiotoxicity.	
This	problem	was	initially	identified	some	20	years	ago	with	cardiotoxic	deaths	oc‐
curring	with	astemizole	and	terfenadine,	two	early	sgAHs.	In	this	review,	we	discuss	
the	mechanisms	 and	 assessments	 of	 potential	 cardiotoxicity	 of	 H1	 antihistamines	
when	updosed	to	four	times	their	 licensed	dose.	In	particular,	we	have	focused	on	
the	 potential	 of	 H1	 antihistamines	 to	 block	 hERG	 (human	 Ether‐a‐go‐go‐Related	
Gene)	voltage‐gated	K+	 channels,	also	known	as	Kv11.1	channels	according	 to	 the	
IUPHAR	classification.	Blockade	of	these	channels	causes	QT	prolongation	leading	
to	torsade	de	pointes	that	may	possibly	degenerate	into	ventricular	fibrillation	and	
sudden	death.	We	considered	 in	detail	bilastine,	cetirizine,	 levocetirizine,	ebastine,	
fexofenadine,	 loratadine,	desloratadine,	mizolastine	and	rupatadine	and	concluded	
that	all	these	drugs	have	an	excellent	safety	profile	with	no	evidence	of	cardiotoxic‐
ity	even	when	updosed	up	to	four	times	their	standard	licensed	dose,	provided	that	
the	prescribers	carefully	consider	and	rule	out	potential	risk	factors	for	cardiotoxicity,	
such	as	the	presence	of	inherited	long	QT	syndrome,	older	age,	cardiovascular	disor‐
ders,	hypokalemia	and	hypomagnesemia,	or	the	use	of	drugs	that	either	have	direct	
QT	prolonging	effects	or	inhibit	sgAH	metabolism.
K E Y W O R D S
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1  | INTRODUC TION
The	 symptoms	 of	 chronic	 urticaria,	 be	 it	 chronic	 spontaneous	 ur‐
ticaria	 (CSU)	 or	 chronic	 inducible	 urticaria	 (CindU),	 are	 mediated	
primarily	 by	 the	 actions	 of	 histamine	 on	 H1	 receptors	 located	 on	
endothelial	cells	(the	weal)	and	on	sensory	nerves	(neurogenic	flare	
and	pruritus).	The	burden	of	CSU,	which	 is	defined	as	 the	sponta‐
neous	appearance	of	signs	and	symptoms	of	urticaria	for	more	than	
6	weeks,1	 is	 substantial	 for	 patients,	 their	 family	 and	 friends,	 the	
healthcare	system	and	society.	Continuous	treatment	with	second‐
generation	H1	 antihistamines	 (sgAHs)	 is	 of	 eminent	 importance	 in	
the	 treatment	 of	 patients	 with	 CSU.	 However,	 many	 patients	 are	
poorly	responsive	to	licensed	doses	of	antihistamines.	In	these	pa‐
tients,	 the	current	EAACI	/	GA2LEN/EDF/WAO	guideline	 for	urti‐
caria	 suggests	 updosing	 of	 sgAHs	 up	 to	 fourfold.1	However,	 such	
updosing	 is	 off‐label,	 and	 consequently,	 the	 responsibility	 resides	
with	 the	prescribing	physician.	 In	 this	case,	 the	safety	of	 the	drug	
when	used	above	its	licensed	dose	is	of	paramount	importance.	This	
issue	is	of	unquestionable	clinical	relevance,	considering	that	astem‐
izole	and	terfenadine,	two	of	the	first	marketed	sgAHs,	have	been	
linked	to	one	of	the	most	serious	cases	of	unexpected	toxicity	after	
marketing	approval:	delayed	ventricular	 repolarization	 (QT	 interval	
prolongation)	leading	to	torsade	de	pointes	(TdP)	possibly	degener‐
ating	into	ventricular	fibrillation	and	causing	sudden	death.2‐6
Over	15	years	have	lapsed	since	the	cardiotoxicity	of	sgAHs	was	
reviewed	in	a	consensus	paper,7	which	did	not,	however,	specifically	
address	the	updosing	issue.	Therefore,	in	this	manuscript,	we	have	
re‐addressed	the	mechanisms	for	potential	cardiotoxicity	of	antihis‐
tamines,	summarized	the	tests	used	to	investigate	this	and	reviewed	
the	 cardiac	 safety	 profiles	 of	 9	 sgAHs	 used	 in	 the	 treatment	 of	
chronic	urticaria.	We	hope	that	this	will	eliminate	the	nagging	doubt	
about	the	potential	of	cardiotoxicity	with	updosing	with	an	H1 an‐
tihistamine	 in	 the	 treatment	of	patients	with	chronic	spontaneous	
urticaria.
2  | MECHANISMS AND A SSESSMENTS OF 
C ARDIOTOXICIT Y OF H1 ANTIHISTAMINES
The	mechanism	most	frequently	involved	in	cardiotoxicity	induced	
by	sgAHs	is	the	blockade	of	hERG	(human	Ether‐a‐go‐go‐Related	
Gene,	Kv11.1)	voltage‐gated	K+	 channels	 (Figure	1).	These	chan‐
nels	 contribute	 to	 cardiac	 repolarization	 by	 carrying	 the	 IKr cur‐
rent	 and,	 therefore,	 their	 blockade	 causes	QT	 prolongation	 and	
ultimately	torsade	de	pointes.8‐13	The	molecular	determinants	for	
histamine	H1	receptor	and	hERG	channel	affinities	are	completely	
unrelated	for	both,	first‐generation	AHs12	and	sgAHs	(Figure	1).9 
For	most	H1	 antihistamines,	 the	 plasma	 concentrations	 for	 anti‐
histaminic	activity	are	much	lower	than	those	required	for	hERG	
channel	activation,	and	only	when	they	are	similar	is	there	an	en‐
hanced	risk	of	a	problem.	On	this	conceptual	basis,	it	has	been	pro‐
posed	that	the	ratio	between	the	hERG	IC50	(ie	the	concentration	
of	drug	that	causes	a	50%	decrease	in	the	current	carried	by	hERG	
channels)	and	the	antihistaminic	response	EC50	(ie	the	concentra‐
tion	of	drug	that	causes	the	50%	of	the	desired	anti‐allergic	effect)	
could	be	used	as	an	 indicator	of	the	arrhythmogenic	potential	of	
sgAHs,	 defining	 a	 so‐called	 cardiac	 safety	 index	 (CSI).14	 Specific	
problems	arise,	however,	when	trying	to	define	CSI	threshold	lev‐
els	below	which	a	drug	has	to	be	considered	as	potentially	danger‐
ous.	Cavero	et	al14	suggested	that	the	CSI	threshold	should	be	set	
at	30,	although	additional	factors	contributing	to	a	more	complete	
definition	of	the	risk/benefit	ratio	for	each	2ndGAH	should	be	also	
taken	into	account.	In	support	of	this	view,	Redfern	and	co‐work‐
ers	 highlighted	 that	 the	 CSI	 for	 the	 cardiotoxic	 sgAHs	 terfena‐
dine	 and	 astemizole,	 calculated	 as	 the	 ratio	 between	 hERG	 IC50 
and	the	effective	drug	therapeutic	plasma	concentration	 (ETPC),	
was	 <	 30,	while	 >	 30	 values	 are	 reported	 for	 safer	 sgAHs	 such	
as	cetirizine,	loratadine,	mizolastine,	ebastine	and	fexofenadine.15 
Values	of	CSI	>	30	times	the	threshold	are	a	strong	argument	 in	
support	 of	 the	 cardiovascular	 safety	 of	 antihistamine	 updosing	
F I G U R E  1  Diagrammatic	
representation	of	the	histamine	H1 
receptor	and	the	hERG	channel	in	
biological	membranes.	Structurally	the	
binding	sites	have	completely	different	
structures.	While	H1	antihistamines	have	
strong	binding	to	histamine	H1	receptors,	
a	different	part	of	the	molecule	has	
very	weak	or	negligible	binding	to	the	
hERG	channel.	Consequently,	potential	
cardiotoxicity	is	not	a	class	effect
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considering	 that	all	drugs	belonging	 to	 this	class	have	 linear	and	
largely	predictable	pharmacokinetics	and	that	plasma	concentra‐
tions	 are	 roughly	 expected	 to	 increase	 proportionally	when	 the	
drug	is	updosed.	Most	sgAHs	are	tightly	bound	to	plasma	proteins	
and	 display	 rather	 low	 distribution	 volumes.16	 Therefore,	 given	
that	only	the	free	drug	fraction	is	available	to	interact	with	hERG	
channels	 and	 that,	 in	 most	 cases,	 therapeutic	 drug	 monitoring	
does	not	discriminate	between	free	and	bound	fractions,	it	seems	
reasonable	 to	 assume	 that	 the	 drug	 concentration	 effectively	
available	to	block	hERG	will	be	much	lower	than	the	total	plasma	
concentration;16	as	a	matter	of	fact,	the	unbound	ETPC	was	used	
by	Redfern15	to	calculate	CSI.
While	these	considerations	predict	sgAH	updosing	to	be	gener‐
ally	safe,	doctors	need	to	be	particularly	aware	of	the	risk	factors	
known	 to	 precipitate	 arrhythmic	 episodes	 observed	 at	 recom‐
mended	doses	of	sgAHs;	these	include	concomitant	use	of	QT	pro‐
longing	drugs	and	of	drugs	that	can	disproportionally	increase	the	
plasma	concentrations	of	 sgAHs	by	pharmacokinetic	 interactions,	
electrolyte	 unbalances	 such	 as	 hypokalemia	 or	 hypomagnesemia,	
previous	cardiac	dysfunction	and	congenital	long	QT	syndrome.
The	 identification	 of	 hERG	 as	 a	 specific	molecular	 target	 for	
drug‐induced	proarrhythmic	effects	has	led	to	several	attempts	to	
standardize	the	preclinical	assessment	of	the	IC50	for	hERG	block,	
as	summarized	in	the	S7B	ICH	Harmonised	Tripartite	Guideline	on	
the	“Non	clinical	evaluation	of	the	potential	for	delayed	ventricular	
repolarization	 (QT	 interval	prolongation)	by	human	pharmaceuti‐
cals.”17	This	document	was	 then	 followed	and	complemented	by	
the	ICH	E14	Guideline	entitled	“The	clinical	evaluation	of	QT/QTc	
interval	prolongation	and	proarrhythmic	potential	for	non	anti‐ar‐
rhythmic	drugs,”	defining	the	characteristic	of	the	so‐called	thor‐
ough	 QT	 (TQT)	 study,	 which	 represents	 the	 reference	 protocol	
for	 drug	 proarrhythmic	 risk	 assessment	 for	 regulatory	 purposes	
using	 a	12‐lead	ECG	 recording.18	 Briefly,	 in	 a	 typical	 TQT	 study,	
the	QT	interval	 is	corrected	for	heart	rate	with	specific	formulas	
such	 as	 the	 Fridericia's	 correction;	 moreover,	 a	 positive	 control	
represented	by	a	drug	unequivocally	proven	to	prolong	QTc	is	al‐
ways	 included,	 and	 candidate	drugs	 are	 investigated	not	 only	 at	
the	recommended	therapeutic	dose	but	also	at	higher	doses	(usu‐
ally	 threefold),	 a	 critical	 issue	 for	our	updosing	perspective.	The	
ICH	E14	Guideline	was	first	issued	in	2004	(thus	after	the	publica‐
tion	of	our	previous	consensus	paper7).	Therefore,	no	TQT	studies	
were	performed	with	sgAH	drugs	licensed	before	that	date.	At	the	
time	of	writing,	only	bilastine,	levocetirizine	and	rupatadine	have	
been	investigated	in	formal	TQT	studies.19‐22	For	all	other	sgAHs,	
non‐ICH	E14	compliant	data	are	available,	which,	however,	often	
includes	doses	larger	than	those	recommended.
3  | C ARDIAC SAFET Y OF SGAHS USED AT 
HIGHER THAN STANDARD DOSES
The	next	paragraphs	summarize	relevant	preclinical	(hERG	blockade)	
and	 clinical	 (plasma	 concentration	 values,	 TQT/	 conventional	 ECG	
studies)	 information	regarding	the	cardiovascular	safety	of	specific	
sgAHs,	with	special	reference	to	updosing	issues	(Table	1).
3.1 | Bilastine
The	recommended	dose	of	the	benzimidazole‐piperidine	sgAH	bi‐
lastine	 is	 20	mg/day.23,24	 This	 drug	 has	 optimal	 pharmacological	
properties	for	updosing	 including	a	high	selectivity	for	H1	 recep‐
tors,	 the	 lack	 of	 a	 significant	 CYP450‐mediated	metabolism	 and	
the	predicted	poor	 retention	 in	 the	brain	being	a	good	substrate	
for	 P‐glycoprotein‐mediated	 transport.25	 Importantly,	 updosing	
is	also	expected	not	to	impact	significantly	on	cardiovascular	risk.	
Indeed,	the	IC50	for	hERG	blockade	in	vitro	is	between	6500	and	
17	170	nM,23	whereas	Cmax	at	steady	state	was	about	2‐10	times	
lower	in	patients	treated	with	single	or	repeated	doses	of	20	and	
100	mg/day22	(Table	1).	A	formal	TQT	study	confirmed	the	lack	of	
significant	effects	on	cardiac	repolarization	of	bilastine	doses	five‐
fold	 higher	 than	 those	 recommended.20,22	 The	 clinical	 evidence	
accumulated	 so	 far	 confirms	 the	 safety	 of	 bilastine	 updosing	 in	
patients	with	cold	urticaria,26	chronic	spontaneous	urticaria27 and 
pruritus.28
3.2 | Cetirizine and levocetirizine
Cetirizine,	the	carboxylated	metabolite	of	hydroxyzine,	is	a	sgAH	of	
the	piperazine	family	with	very	low	sedating	and	anticholinergic	ac‐
tivities.29	Cetirizine	has	a	chiral	centre	and,	therefore,	exists	in	two	
enantiomeric	 forms,	 R‐	 and	 L‐cetirizine,	 of	 which	 only	 L‐cetirizine	
(levocetirizine)	 is	active	on	H1	 receptors.	Levocetirizine	has	a	simi‐
lar	tolerability	and	a	higher	potency	than	the	parent	racemic	form,	
cetirizine.30‐32
The	recommended	daily	dose	of	cetirizine	and	levocetirizine	is	10	
and	5	mg/day,	respectively.33,34
Both	 cetirizine	 and	 levocetirizine	 have	 been	 successfully	 and	
safely	updosed	for	 the	treatment	of	cholinergic	and	chronic	spon‐
taneous	 urticaria.35‐43	 Both	 drugs	 appear	 remarkably	 safe	 from	 a	
cardiovascular	 point	 of	 view,	 and	 they	 are	 well	 suited	 for	 updos‐
ing.	Cetirizine	is	inactive	on	hERG	channels	in	concentrations	up	to	
3000	 nM	 in	mammalian	 cells.44,45	 This	 is	 higher	 than	 the	Cmax	 at‐
tained	after	a	single	or	repeated	administration	at	doses	up	to	three‐
fold	 higher	 than	 the	 recommended	 one30,46	 (Table	 1).	 Concerning	
levocetirizine,	no	effect	on	cloned	hERG	channels	was	observed	in	
Xenopus	oocytes	at	concentrations	up	 to	30	000	nM.47	This	drug	
reaches	 peak	 plasma	 concentrations	 of	 <1000	 nM	 after	 single	 or	
repeated	administrations	of	the	recommended	5	mg	dose,	whereas	
few	 data	 are	 available	 on	 the	 higher	 doses	 (Table	 1).	 Remarkably,	
however,	a	Cmax	value	of	about	3000	nM	was	recorded	in	volunteers	
taking	 a	 single	 sixfold	 higher	 dose	 of	 30	mg.21	 Collectively,	 these	
data	argue	against	a	significant	blockade	of	hERG	channels	 in	vivo	
by	cetirizine	and	levocetirizine.	In	agreement	with	this,	cetirizine	did	
not	prolong	the	QTc	interval	at	doses	of	up	to	60	mg/day	(six	times	
the	recommended	dose)	in	a	non‐TQT	study	performed	before	the	
publication	of	the	(ICH)	E14	guidance.48	The	safety	of	levocetirizine	
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up	to	30	mg	(sixfold	the	recommended	dose)	was	demonstrated	in	a	
formal	TQT	study.21
3.3 | Ebastine
Ebastine	is	a	second‐generation	piperidine	antihistamine	structur‐
ally	 related	 to	 terfenadine	whose	 recommended	 dose	 is	 10	mg/
day.	 After	 being	 absorbed,	 ebastine	 is	 almost	 completely	 con‐
verted	 by	 CYP2J2	 in	 the	 liver	 into	 the	 active	 metabolite	 care‐
bastine.49	 It	 is	carebastine	that	 is	usually	measured	in	plasma	for	
pharmacokinetic	studies.50	In	Xenopus	oocytes,	ebastine	blocked	
heterologously	 expressed	 hERG	 channels	 with	 a	 similar	 affin‐
ity	 (Kd	=	300	vs	400	nM)	but	with	 lesser	efficacy	 (46%	vs	80%)	
than	 terfenadine.51	 No	 data	 are	 available	 on	 the	 effect	 of	 the	
active	 metabolite	 carebastine	 on	 recombinant	 hERG,	 but	 Moss	
and	 Morganroth52	 mention	 a	 personal	 communication	 by	 Roy	
and	Brown	stating	that,	unlike	ebastine,	this	molecule	is	inactive.	
Carebastine	shows	almost	linear	kinetics	with	Cmax	values	linearly	
related	to	the	dose	when	single	ebastine	doses	of	10,	30,	40,	50	
and	90	mg	are	used.53	Data	obtained	in	human	studies	suggest	a	
good	cardiovascular	tolerability	of	ebastine	even	when	updosed.	
Indeed,	when	Moss	et	al54	performed	a	pooled	analysis	of	the	ECG	
findings	obtained	 in	 the	preapproval	clinical	 trials	with	ebastine,	
they	found	no	QTc	prolongation	at	the	doses	of	10	and	20	mg	but	
slight	and	non‐clinically	relevant	QTc	interval	increase	when	given	
at	doses	of	60	and	100	mg/day.55
TA B L E  1  Selected	pharmacodynamic	and	pharmacokinetic	parameters	of	the	sgAHs	mentioned	in	the	text
 hERG IC50
a  (nM)
H1 receptor 
Ki
b  (nM)
Protein binding 
(%)  
Cmax standard 
dose (nM) Cmax Updosing (nM)
BILASTINE 6500‐1717023 64105 84‐9023 Single	dose 490106 Fivefold:	3407106
Repeated	doses 44922 Fivefold:	304122
CETIRIZINE No	effect	up	to	
300044,45
47107 9333 Single	dose 55046 Threefold:	174046
Repeated	doses 79946 Threefold:	214046
DESLORATADINE 195074 0.9107 82‐87108 Single	dose 7.076 Fourfold:	26.076
Repeated	doses 12.8109 Ninefold:	161.265
EBASTINEc  Ebastine:	30051 
carebastine:	
na‐	possibly	
inactive	(see	
text)
Ebastine	:52107 
carebastine:	
10107
Carebastine:	
9850
Single	dose 22053 Threefold:	44053
Fourfold:	62053
Fivefold:	86153
Repeated	doses 260‐320110 Twofold:	793111
FEXOFENADINE 21400057 175107 60‐80112 Single	dose 60	mg:	283112 Threefold	(2.7)c :	649458
180	mg:	358112 Fourfold	(4.4)c :	1272358
Repeated	doses 60	mg	bid:	596112 Threefold	(2.9)c :	312458
 Eightfold	(7.6)c :	932358
LEVOCETIRIZINE No	effect	up	to	
3000047
3113 91‐9234 Single	dose 58621 Sixfold:	334821
Repeated	doses 79234 na
LORATADINE 10100045 138107 97‐9975 Single	dose 5.575 Fourfoldd:	68.375
515074 12.3d 75
Repeated	doses 12.181 na
MIZOLASTINE 35088 22107 98.4114 Single	dose 52789 Fourfold:	226889
Repeated	doses 53989 Fourfold:	244689
RUPATADINE 810094 3.8115 98‐99115 Single	dose 6.396 Tenfold:	38.596
Repeated	doses 7.4596 Tenfold:	552.996
aIC50	stands	for	the	half	maximal	inhibitory	concentration,	that	is	the	concentration	of	a	given	drug	that	causes	a	50%	inhibition	of	a	specific	biologi‐
cal	or	biochemical	activity.	In	the	specific	case	of	sgAHs	and	hERG	activity,	it	indicates	the	concentration	of	the	antihistamine	drug	needed	to	cause	a	
50%	decrease	in	the	amplitude	of	the	K+	currents	carried	by	these	channels	in	electrophysiological	experiments	in	vitro.
bKi	is	the	inhibitory	constant	and	measures	the	affinity	of	a	certain	drug	inhibitor	for	its	target;	in	the	specific	case	reported	in	this	table,	it	measures	
the	affinity	of	the	indicated	sgAHs	for	H1	receptors	in	binding	experiments	in	vitro.	It	is	important	to	mention	here	that	Ki	and	binding	IC50	are	not	
identical	because	the	latter	but	not	the	former	depend	on	the	experimental	condition	(eg	on	the	concentration	of	the	target	protein).	For	competitive	
agonists	and	antagonists,	Ki	can	be	obtained	from	IC50	data	by	using	the	Cheng	and	Prusoff	equation.
116
cFexofenadine	doses	used	in	ref.57	are	not	exact	multiples	of	the	therapeutic	doses.	The	closest	values	to	the	upscaled	doses	have	been	reported,	and	
the	exact	ratios	to	therapeutic	doses	are	reported	in	parentheses.
dData	obtained	with14C‐loratadine.
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3.4 | Fexofenadine
Fexofenadine	 is	 the	 active	 carboxylated	 metabolite	 of	 terfena‐
dine	 that	 is	 generated	 in	 vivo	by	CYP3A4‐dependent	oxidative	N‐
dealkylation.56	The	 recommended	dose	of	 fexofenadine	 is	180	mg	
orally	once	a	day	or	60	mg	orally	2	times	a	day.	No	cardiotoxicity	is	
expected	when	updosing	fexofenadine	because	the	peak	concentra‐
tions	attained	even	after	the	administration	of	high	doses	of	the	drug	
are	more	 than	 tenfold	 lower	 than	 the	 IC50	 for	 human	hERG	chan‐
nels	(Table	1).57	More	specifically,	Russel	et	al58	found	that	the	fex‐
ofenadine	Cmax	was	at	least	20	times	lower	than	hERG	IC50		after	the	
administration	of	a	single	dose	of	800	mg	(4.4	fold	higher	than	the	
recommended	dose	of	180	mg/day)	or	after	the	repeated	administra‐
tion	of	690	mg	twice	daily	(about	8	fold	higher	than	the	recommended	
dose	of	180	mg/day).	Pratt	et	al59	performed	a	pooled	retrospective	
analysis	 of	 the	 data	 on	 cardiovascular	 safety	 collected	 during	 the	
clinical	trials	with	fexofenadine	(in	doses	up	to	800	mg	once	daily	or	
690	mg	twice	daily)	in	healthy	subjects	and	patients	with	seasonal	al‐
lergic	rhinitis.	Overall	more	than	2100	ECGs	and	approximately	6000	
clinical	histories	were	reviewed	with	no	evidence,	respectively,	of	QT	
prolongation	and	cardiac	 toxicity	even	at	 the	highest	 fexofenadine	
doses.59	In	addition,	fexofenadine	doses	up	to	240	and	540	mg/day	
were	used	in	studies	on	urticaria	in	Japan60	and	India,37	respectively,	
without	any	significant	unwanted	cardiac	effect.
3.5 | Loratadine and desloratadine
Loratadine	 is	 a	 second‐generation	 piperidine	 antihistamine	 drug	
structurally	 related	to	azatadine	and	cyproheptadine.61	Loratadine	
is	 very	well	 tolerated	 because	 it	 lacks	 anticholinergic	 activity	 and	
does	 not	 cross	 the	 blood‐brain	 barrier	 to	 cause	 sedation.62	 After	
oral	 administration,	 this	 drug	 undergoes	 extensive	 first	 pass	 me‐
tabolism	being	converted	by	CYP3A4	and	CYP2D6	to	its	active	me‐
tabolite	 descarboethoxyloratadine	 (desloratadine),	 which	 is	 about	
four	 times	more	potent	 at	H1	 receptors	 than	 loratadine	 itself.
62,63 
Desloratadine	has	been	developed	as	a	drug	with	clinical	indications	
similar	to	those	of	loratadine	but	with	higher	potency,	longer	half‐life	
and	lower	binding	to	plasma	proteins.64,65	The	recommended	doses	
of	 loratadine	and	desloratadine	are	10	and	5	mg/day,	respectively.	
Both	drugs	have	been	used	in	several	studies	at	higher	than	standard	
doses,	 including	some	in	patients	with	urticaria.36,40,66‐72	Updosing	
of	loratadine	and	desloratadine	to	up	to	fourfold	the	standard	dose	
does	 not	 impose	 a	 significant	 risk	 of	 arrhythmias.	 Loratadine	 and	
desloratadine	block	cloned	hERG	channels	in	mammalian	cells	with	
much	lower	potency	than	terfenadine	(330	nM),	with	estimated	IC50 
values	of	about	5000‐100000	nM	for	the	former	and	1950	nM	for	
the	latter.44,45,73,74	These	IC50	values	are	more	than	300	times	higher	
than	the	maximal	plasma	concentration	attained	by	 loratadine	and	
desloratadine	 after	 a	 single	 administration	 of	 the	 recommended	
daily	doses	of	10	and	5	mg,	respectively.75‐77	Importantly,	Cmax	values	
were	more	than	100	times	lower	than	hERG	IC50	values	when	lorata‐
dine	or	desloratadine	was	updosed	twofold	or	fourfold75‐77	(Table	1).	
Likewise,	 during	 the	 repeated	 administration	 of	 recommended,	
double	and	fourfold	doses	of	loratadine,	Cmax	was	almost	a	hundred	
times	lower	than	hERG	IC50	at	steady	state	(Table	1).
75	Collectively,	
these	 data	 point	 to	 remarkable	 cardiovascular	 safety	 of	 both	 lo‐
ratadine	 and	desloratadine	even	when	updosed	as	 also	 confirmed	
in	clinical	 trials	 in	humans	 that	were	performed	by	a	non‐TQT	ap‐
proach	before	the	ICH	E4	guideline	approval.	Specifically,	no	signifi‐
cant	effect	on	cardiac	repolarization	was	observed	with	loratadine	
at	the	recommended	dose	of	10	mg,78‐81	when	given	for	two	weeks	
at	a	twofold	higher	dose,82	or	when	used	for	13	weeks	at	a	fourfold	
higher	dose.83	Also,	desloratadine	did	not	prolong	QTc	when	given	
at	 the	 recommended	5	mg	daily	dose84	 or	 at	 the	dose	of	7.5	mg/
day.85,86	 No	 published	 data	 are	 available	 for	 higher	 desloratadine	
doses	with	the	only	exception	of	an	abstract	showing	the	lack	of	any	
significant	prolongation	of	QTc	after	the	administration	for	10	days	
at	doses	ninefold	higher	than	those	recommended.87
3.6 | Mizolastine
The	recommended	dose	of	the	piperidine	sgAH	mizolastine	is	10	mg.	
Mizolastine	blocks	hERG	channels	with	an	IC50	of	3400	nM	in	Xenopus	
oocytes	 and	 of	 350	 nM	 in	mammalian	 cells.88	 The	Cmax	 of	mizolas‐
tine	was	527	nM	after	the	administration	of	a	single	10	mg	dose	and	
2268	nM	when	a	40	mg	single	dose	was	given.89	At	steady	state,	after	
the	repeated	administration	of	10	and	40	mg	daily	doses	for	7	days,	
Cmax	 values,	 respectively,	 of	 539	 and	 2446	 nM	 were	 obtained.
89 
Though	these	values	are	close	to	the	IC50	for	hERG	blockade,	the	free	
concentration	of	mizolastine	that	is	actually	available	to	interact	with	
cardiac	hERG	channels	is	much	lower	(around	10	nM)	because	of	the	
high	binding	to	plasma	proteins.90	The	cardiovascular	safety	of	mizo‐
lastine	in	doses	higher	than	those	recommended	was	investigated	in	
two	non‐TQT	studies.	 In	 the	 first	of	 these	studies,	Chaufour	et	al.89 
measured	 the	effect	on	QTc	of	10,	20	and	40	mg	mizolastine	given	
as	 single	or	 repeated	daily	doses	 for	7	days,	without	any	 significant	
change	 in	ventricular	 repolarization.	Similar	 results	were	obtained	 in	
the	second	study,	by	Delauche‐Cavallier	et	al.,91	who	tested	the	effect	
of	mizolastine	up	to	75	mg	single	dose	and	40	mg	repeated	dose,	again	
without	any	drug‐induced	QTc	prolongation.	Therefore,	available	evi‐
dence	suggests	that	mizolastine	can	be	safely	updosed	fourfold	with‐
out	inducing	any	significant	change	in	cardiac	risk.
3.7 | Rupatadine
Rupatadine	is	a	sgAH	of	the	piperidine	subfamily	which	differs	from	
other	sgAHs	in	its	ability	to	also	block	PAF	receptors.92,93	The	rec‐
ommended	 dosage	 of	 rupatadine	 is	 10	mg	 once	 a	 day.	 Studies	 in	
vitro	showed	that	rupatadine	blocks	hERG	channels	with	a	 IC50	of	
8100 nM.94	As	previously	reported	also,	the	hERG	IC50	of	deslorat‐
adine,	 the	major	metabolite	 generated	by	 rupatadine	 in	 vivo,	 is	 in	
the	μM	range.	After	oral	administration	of	single	or	of	repeated	(five	
days)	standard	10	mg	dose	doses,	rupatadine	Cmax	was	always	about	
2000‐fold	 lower	 than	 the	 aforementioned	 average	 IC50	 for	 hERG	
blockade	(Table	1).95,96	Church	and	colleagues2	showed	that	after	a	
single	dose	of	40	mg	(fourfold	higher	than	the	recommended	dose),	
6  |     CATALDI eT AL.
rupatadine	Cmax	was	36.38	nM,	whereas	Taubel	et	al.
96	 found	val‐
ues	of	38.5	and	552.9	nM	in	Caucasian	subjects	receiving	100	mg	
rupatadine	(ten	times	the	recommended	dose)	as	a	single	or	as	re‐
peated	 doses,	 respectively.	 An	 ICH‐compliant	 TQT	 study	 showed	
that	rupatadine	at	a	dose	of	100	mg,	tenfold	higher	than	the	recom‐
mended	dose,	did	not	induce	significant	changes	in	cardiac	repolari‐
zation	neither	when	given	as	a	single	dose	nor	when	administered	
once	a	day	for	5	days.19	Similar	results	have	recently	been	reported	
in	Japanese	volunteers	by	Taubel	et	al.96	 In	conclusion,	rupatadine	
updosing	does	not	seem	to	increase	the	length	of	cardiac	repolariza‐
tion	to	any	extent.
4  | CONCLUSIONS
As	stated	in	the	introduction,	the	first‐line	treatment	of	patients	with	
CSU	is	the	use	of	standard	dosed	non‐sedating	second‐generation	
H1	antihistamines.
1	However,	many	patients	with	CSU	do	not	show	
complete	control	of	their	disease	with	standard	doses.97	In	these	pa‐
tients,	updosing	of	up	to	fourfold	higher	than	standard	doses	of	their	
H1	antihistamine	 is	 recommended	by	the	current	EAACI/GA
2LEN/
EDF/WAO	guideline	 for	urticaria.1	Several	 studies	have	confirmed	
that	treatment	of	CSU	by	higher	than	standard	doses	of	H1	antihista‐
mine,	that	is	updosing	of	an	sgAH,	is	more	effective	than	treatment	
with	the	standard	dose	for	most	sgAHs.27,36,38,72,98,99	No	cardiotox‐
icity	was	reported	in	any	of	these	studies.	In	contrast	to	updosing,	
one	study	has	 shown	 that	 the	use	of	a	combination	of	H1	 antihis‐
tamines	each	at	their	 licensed	dose	 is	 less	effective	than	updosing	
with	a	single	antihistamine.100	The	authors	suggest	that	the	reason	
for	this	is	unknown	interactions	and	addition	of	side‐effects	in	the	
combination	therapy.
Despite	the	clear	guidelines	and	the	overwhelming	evidence	of	
the	clinical	benefit	of	updosing,	a	recent	survey	of	528	patients	with	
uncontrolled	 CSU	 and	who	were	 eligible	 for	 treatment	 escalation	
showed	that	only	3%	received	up	dosing	of	H1	antihistamines.
101	The	
reasons	for	this	are	not	well	understood	but	are	held	to	include	that	
updosing	is	off‐label	and	perceived	to	be	linked	to	reduced	cardiac	
safety.
Our	present	review	clearly	shows	that	sgAHs,	at	up	to	fourfold	
their	standard	dose,	have	excellent	cardiac	safety	profiles,	although	
there	are	differences	in	the	quality	of	the	supporting	evidence	for	the	
safety	of	the	different	drugs.	However,	lower	quality	evidence	does	
not	mean	lower	cardiac	safety.	A	review	by	Olasińska‐Wiśniewska102 
supports	our	findings	and	concludes	that	such	phenomena	are	po‐
tentially	manifested	only	 in	the	cases	of	high	overdose	far	beyond	
the	suggested	therapeutic	levels.	A	potential	limitation	of	our	study,	
however,	is	that	the	data	that	we	reviewed	were	mainly	obtained	ei‐
ther	in	studies	in	vitro	or	in	healthy	volunteers.	Therefore,	we	cannot	
exclude	that	some	difference	could	exist	 in	patients	affected	with	
chronic	urticaria.	Furthermore,	there	are	certain	groups	of	patients,	
especially	the	ones	with	inherited	long	QT	syndrome,	the	elderly	(ie	
according	 to	WHO	definitions,	people	older	 than	65	years103)	 and	
patients	with	cardiovascular	diseases,	who	require	special	attention.	
These	patients	should	be	warned	not	to	overdose	their	prescribed	
antihistamines	 and	 not	 to	 combine	 them	with	 drugs	 such	 as	 anti‐
fungal	drugs	and	macrolides,	or	food	and	beverages,	such	as	grape‐
fruit	 juice,	 that	 inhibit	 their	 metabolism	 by	 CYPs	 (mainly	 but	 not	
exclusively	CYP3A4),	nor	with	any	drugs	that	prolong	QT	intervals,	
such	 as	 anti‐arrhythmics,	 antimicrobials,	 tricyclic	 antidepressants,	
neuroleptics	 and	 prokinectics.	A	 special	 caution	 is	 also	 advised	 in	
the	presence	of	electrolyte	unbalances	such	as	hypokalemia	and	hy‐
pomagnesemia,	and	it	should	be	remembered	that	these	conditions	
can	be	precipitated	by	proton	pumps	inhibitors,	drugs	that,	in	clinical	
practice,	are	usually	considered	harmless.104
Our	conclusion	is	that	the	sgAHs	discussed	in	this	review,	namely	
bilastine,	 cetirizine,	 levocetirizine,	 ebastine,	 fexofenadine,	 lorata‐
dine,	desloratadine,	mizolastine	and	rupatadine,	all	have	an	excellent	
safety	profile	with	no	evidence	of	cardiotoxicity	even	at	up	to	four	
times	their	standard	licensed	dose.
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